ACE910

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Congenital hemophilia A, a relatively common and sometimes life-threatening bleeding disorder, is caused by inherited deficiency… (More)
Is this relevant?
2016
2016
ACE910 is a recombinant humanized bispecific antibody that binds to activated factor IX and factor X and mimics the cofactor… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2016
2016
The development of inhibitors to factor VIII (FVIII) or factor IX (FIX) remains a major treatment complication encountered in the… (More)
Is this relevant?
Review
2016
Review
2016
There are some issues in the current factor (F)VIII replacement therapy for severe hemophilia A. One is mental and physical… (More)
Is this relevant?
2015
2015
  • Midori Shima
  • [Rinsho ketsueki] The Japanese journal of…
  • 2015
Unmet needs of current hemophilia A treatment include the requirement for frequent intravenous infusions, inhibitor development… (More)
Is this relevant?
Review
2015
Review
2015
For more than 3 decades, the scientific community has pursued gene correction of hemophilia, with the goal that an individual… (More)
Is this relevant?
2014
2014
BACKGROUND We previously reported that a humanized anti-factor IXa/X bispecific antibody, hBS23, mimics the function of FVIII… (More)
Is this relevant?
2014
2014
ACE910 is a humanized anti-factor IXa/X bispecific antibody mimicking the function of factor VIII (FVIII). We previously… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2014
2014
BACKGROUND We previously reported that a humanized anti-factor IXa/X bispecific antibody, hBS23, mimics the function of FVIII… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?